Healthcare Industry News: abdominal aortic aneurysm
News Release - May 1, 2009
Integra LifeSciences Will Feature the New LimiTorr Volume Limiting CSF Drainage System At AANSThe Next Evolution in Cerebral Spinal Fluid Drainage
PLAINSBORO, N.J., May 1, 2009 -- (Healthcare Sales & Marketing Network) -- Integra LifeSciences Holdings Corporation (NasdaqGS:IART ) announced today that it will feature the LimiTorr(TM) Volume Limiting CSF Drainage System at the upcoming 2009 American Association of Neurological Surgeons Annual Meeting in San Diego, CA, May 2 - 6. The LimiTorr(TM) system is the latest addition to Integra's cerebral spinal fluid (CSF) drainage product line and the first volume-limiting CSF management system on the market. The LimiTorr(TM) system was designed with the help of Michael McDermott, MD, Professor and Vice-Chairman at the University of California, San Francisco, Department of Neurosurgery.
The LimiTorr(TM) Volume Limiting CSF Drainage System can be used for both lumbar and ventricular drainage. It includes a volume-limiting valve mechanism designed to halt drainage when the pre-determined volume limit of 20 mL or 30 mL is met. This safety mechanism helps prevent CSF overdrainage that may lead to subdural hematomas, brainstem herniation or death.
``The LimiTorr(TM) system is an innovative product that may enhance patient care, and further differentiates Integra's portfolio of CSF drainage systems from the competition,'' said John Barrett, Vice President of Marketing and Product Development for Integra NeuroSciences.
CSF drainage is an important component of managing the intracranial pressure of a neuro-compromised patient or a patient undergoing abdominal aortic aneurysm surgery. It is estimated that over 300,000 lumbar or ventricular drainage procedures are performed annually in the United States, representing a $100 million market.
The LimiTorr(TM) Volume Limiting CSF Drainage System will be sold by the Integra NeuroSciences direct sales organization. Integra NeuroSciences is a leading provider of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neuro-trauma, and related critical care. Integra NeuroSciences' direct selling effort in the United States and Europe involves more than 150 professionals. In all other markets, Integra NeuroSciences' products are sold through a network of distributors.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of clinically relevant, innovative, and cost-effective surgical implants and medical instruments. Integra's products, used primarily in neurosurgery, orthopedics and general surgery, are used to treat millions of patients every year. The Company's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. For more information visit http://www.Integra-LS.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of Integra products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use the LimiTorr Volume Limiting CSF Drainage System may affect the prospects for its use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading ``Risk Factors'' included in section IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2008 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
Source: Integra LifeSciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.